Abstracts tagged "Antibodies"

Abstract Number: 534 • 2015 ACR/ARHP Annual Meeting
Antibodies to Malondialdehyde-Acetaldehyde Adducts Are Highly Expressed in Rheumatoid Arthritis Synovial Fluid
Rafid Rahman¹, Geoffrey M. Thiele², Andy Hollins³, Michael J. Duryee¹, Daniel Anderson³, Bartlett Hamilton⁴, Kaleb Michaud⁵, Lynell W. Klassen⁶ and Ted R. Mikuls³, ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, NE, ⁵Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁶Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Malondialdehyde-acetaldehyde (MAA) adducts are expressed in synovial tissues in rheumatoid arthritis (RA). Post-translational MAA modifications are pro-inflammatory, promoting robust anti-MAA antibody responses that…
Abstract Number: 2515 • 2015 ACR/ARHP Annual Meeting
MEK5/ERK5, a Lynchpin of Human Cardiac Fibroblast Transdifferentiation to a Scarring Phenotype in Autoimmune Congenital Heart Block
Andrew Markham¹, Robert Clancy², Mukundan Attur³ and Jill P. Buyon², ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY
Background/Purpose: Transplacental passage of maternal autoantibodies (Ab) reactive with the SSA/Ro-SSB/La ribonucleoprotein complex is associated with the development of cardiac injury in the fetus passively…
Abstract Number: 589 • 2015 ACR/ARHP Annual Meeting
Adalimumab Concentration at 16 Weeks of Treatment Is Associated with Treatment Discontinuation within One Year
Mieke F. Pouw^1,2, Denis Mulleman³, Mike T. Nurmohamed^1,4, Theo Rispens⁵, Gilles Paintaud³, Gertjan Wolbink^1,2 and David Ternant³, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Immunopathology, Sanquin Research, Amsterdam, Netherlands, ³Université François-Rabelais de Tours, CNRS 7292, Tours, France, Tours, France, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Anti-drug antibodies (ADAb) in patients treated with adalimumab have been associated with decreased adalimumab concentrations and loss of clinical response, and therefore treatment discontinuation.…
Abstract Number: 2551 • 2015 ACR/ARHP Annual Meeting
Antibodies to Malondialdehyde-Acetaldhyde Adducts Are Increased in the Serum of Mice Following Infection with P. Gingivalis and/or Injection of Citrullinated Mouse Type II Collagen: a Model of Human Disease Response
Geoffrey M. Thiele⁴, Einstein Juma¹, Roxanne Haslam¹, Michael J. Duryee², Anand Dusad³, Carlos D. Hunter², James R. O'Dell⁴, Lynell W. Klassen⁴, Ted R. Mikuls⁴ and Geoffrey M. Thiele⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA complicated by periodontal disease (PD) have been shown to have higher anti-citrullinated protein antibody (ACPA) levels, which have also become predictive…
Abstract Number: 632 • 2015 ACR/ARHP Annual Meeting
Isolated Atrioventricular Block of Unknown Origin in the Adult and Autoimmunity: Diagnostic and Therapeutic Considerations Exemplified By Three Anti-Ro/SSA-Associated Cases
Antonio Brucato¹, Pietro Enea Lazzerini², Pier Leopoldo Capecchi³, Anna Valenti⁴, Lucia Baldi⁵, Maria Romana Bacarelli³, Claudia Nucci⁵, Valentina Moscadelli³, Gabriella Morozzi³, Mohamed Butjdir^6,7,8 and Franco Laghi Pasini³, ¹Internal Medicine, Ospedale Papa Giovanni XXIII Bergamo, Bergamo, Italy, ²Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, ³Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁴Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ⁵Cardiology, University of Siena, Siena, Italy, ⁶Medicine, Cell Biology and Pharmacology, State University of New York at Downstate Medical Center, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸Research Department, VA New York Harbor Healthcare System, New York, NY
Background/Purpose: Circulating anti-Ro/SSA antibodies may rarely affect the adult conduction-system. A direct autoantibody-mediated electrophysiological inhibition of cardiomyocyte calcium-channels (acquired form) or an ante-natal subclinical injury…
Abstract Number: 2922 • 2015 ACR/ARHP Annual Meeting
HLA-Specific Antibody Profile in Renal Transplant Patients with Systemic LUPUS Erythematosus
Diana Girnita¹, Paul Brailey² and Alin Girnita³, ¹Division of Immunology, Allergy & Rheumatology, University of Cincinnati Medical Center, Cincinnati, OH, ²Transplant Immunology Division, University of Cincinnati Medical Center -Hoxworth Blood Center, cincinnati, OH, Oman, ³Transplant Immunology Division, University of Cincinnati Academic Health Center, Hoxworth Blood Center, Cincinnati, OH
Background/Purpose: End stage renal disease due to Systemic lupus erytematosus (SLE) is one of the autoimmune disorder leading to renal transplantation. In this single-center study…
Abstract Number: 633 • 2015 ACR/ARHP Annual Meeting
Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹, Leah Medrano² and Mara McAdams-Demarco³, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Anti-centromere antibodies (ACA) define a subgroup of Sjögren’s syndrome (SS) patients who are often older, have more frequent Raynaud’s phenomenon, and a lower frequency…
Abstract Number: 2951 • 2015 ACR/ARHP Annual Meeting
Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction
Gaurav Gulati¹, Philip Iffland², Damir Janigro², Bin Zhang³ and Michael Luggen⁴, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁴Division of Immunology, University of Cincinnati Medical Center, Cincinnati, OH
Background/Purpose: Cognitive Dysfunction (CD) is one of the most common manifestations of neuropsychiatric SLE (NPSLE) and one of the most devastating. The pathogenesis of CD…
Abstract Number: 635 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹ and Julius Birnbaum², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with Sjögren’s syndrome (SS) and negative SSA/SSB serology (ie. seronegative SS) have phenotypic characteristics different than seropositive ones, and thus may constitute a…
Abstract Number: 3112 • 2015 ACR/ARHP Annual Meeting
Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
RJ Moots¹, Ricardo Xavier², Chi Chiu Mok³, Mahboob U Rahman⁴, Wen-Chan Tsai⁵, Mustafa Al Maini⁶, Karel Pavelka⁷, Ehab Mahgoub⁸, Sameer Kotak⁹, Joan Korth-Bradley¹⁰, Ronald Pedersen¹¹, Linda Mele⁸, Qi Shen⁸ and Bonnie Vlahos⁸, ¹Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ³Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ⁴Perelman School of Medicine, University of Pennsylvania, Philadephia, PA, ⁵Kaohsiung Medical University, Kaohsiung, Taiwan, ⁶Rheumatology, Allergy and Clinical Immunology Division, Mafraq Hospital, Abu Dhabi, United Arab Emirates, ⁷Charles University, Prague, Czech Republic, ⁸GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁹Global Health and Value, Pfizer, New York, NY, ¹⁰GIPB- Clinical Sciences, Pfizer, Collegeville, PA, ¹¹Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with biologics can elicit unwanted immune responses such as antidrug antibodies (ADA), which may decrease their clinical efficacy and increase adverse events. However,…
Abstract Number: 809 • 2015 ACR/ARHP Annual Meeting
Patients with SLE Who Are Anti-Factor Xa IgG Positive Are Less Likely to Have Atherosclerotic Plaque
Claire-Louise Murphy¹, Sara Croca¹, Bahar Artim-Esen², Laura Hanns³, Charis Pericleous¹, Thomas McDonnell¹, Yiannis Ioannou⁴, David A. Isenberg¹, Anisur Rahman¹ and Ian Giles⁵, ¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Rheumatology, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁵Rayne Intitiute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Patients with SLE have an increased risk of cardiovascular disease (CVD), which is not fully explained by traditional risk factors and may be mediated…
Abstract Number: 823 • 2015 ACR/ARHP Annual Meeting
Anti-IFI16 Antibodies in Scleroderma Are Associated with Digital Gangrene
Zsuzsanna McMahan¹, Ami A. Shah², Dhananjay Vaidya³, Fredrick M. Wigley⁴, Antony Rosen⁵ and Livia Casciola-Rosen⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine, School of Medicine, Johns Hopkins, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Mason Lord Bldg Ctr Tower, Johns Hopkins University, School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Our aim was to examine and confirm the association between anti-IFI16 antibodies and clinical features of scleroderma. Methods: Sera from a discovery sample…
Abstract Number: 1151 • 2015 ACR/ARHP Annual Meeting
The Proteomic Profile of Histological Samples Derived from a Surgical Mouse Model of Osteoarthritis Reveals an Unexpected Mode of Action for the Anti-Aggrecanase-2 Monoclonal Antibody CRB0017
Gianfranco Caselli¹, Riccardo Chiusaroli², Michela Visintin³, Tiziana Piepoli², Ornella Letari², Adriana Grotti², Marco Lanza², Antonella De Palma⁴, Dario di Silvestre⁴, Pierluigi Mauri⁴ and Lucio Claudio Rovati², ¹Pharmacology & Toxicology, Rottapharm Biotech Srl, Monza, Italy, ²Rottapharm Biotech Srl, Monza, Italy, ³Rottapharm Biotech Srl, Trieste, Italy, ⁴Institute for Biomedical Technologies - CNR, Segrate, Italy
Background/Purpose : CRB0017 is a novel therapeutic monoclonal antibody that recognizes the spacer domain of aggrecanase-2, a key enzyme in the degradation of extracellular matrix…
Abstract Number: 1366 • 2015 ACR/ARHP Annual Meeting
Natural Antibodies, Not B Cells, Contribute to Acute Cell Death-Induced Inflammation
Hiroshi Kataoka, Rheumatology and Clinical Immunology, Sapporo City General Hospital, Sapporo, Japan
Background/Purpose: Alarmins, such as uric acid, released from dying cells activate inflammasomes and mediate dead cell-induced inflammation (Ref.). Since it is remains unknown whether or…
Abstract Number: 1772 • 2015 ACR/ARHP Annual Meeting
Anti-Pentraxin 3 Antibodies Ameliorate Disease Manifestations and Lupus-like Nephritis in New Zealand Black/New Zealand White F1 Mice
Mariele Gatto¹, Nicola Bassi¹, Anna Ghirardello¹, Roberto Luisetto¹, Silvano Bettio¹, Luca Iaccarino¹, Leonardo Punzi² and Andrea Doria², ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose: Pentraxin 3 (PTX3) is an acute-phase protein released by different cell types including renal epithelial cells and immune-competent cells. PTX3 is able to either…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].